JAMES R. MCARTHUR, M.D.; JOHN W. ATHENS, M.D., F.A.C.P.; MAXWELL M. WINTROBE, M.D., Ph.D., F.A.C.P.; GEORGE E. CARTWRIGHT, M.D., F.A.C.P.
Sixty-seven patients with symptomatic multiple myeloma were studied. Thirty-nine were treated with melphalan. The initial dose of 4 mg by mouth daily was reduced if the white blood count fell below 2,000 to 2,500/mm3. There were significant objective and subjective improvement and increased survival in the melphalan-treated patients as compared with a retrospective control group of 28 patients. The results compare favorably with reported series in which high-dose intermittent regimens were used. Information is insufficient to compare toxicity and complications associated with the two regimens.
JAMES R. MCARTHUR, JOHN W. ATHENS, MAXWELL M. WINTROBE, GEORGE E. CARTWRIGHT. Melphalan and Myeloma: Experience with a Low-Dose Continuous Regimen. Ann Intern Med. 1970;72:665–670. doi: 10.7326/0003-4819-72-5-665
Download citation file:
Published: Ann Intern Med. 1970;72(5):665-670.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use